Neostigmine Versus Sugammadex on Renal Functions

Menoufia University

Status and phase: Active, not recruiting; Phase 4

Conditions: Sugammadex; Neostigmine

Treatments: Drug: Sugammadex; Drug: Neostigmine

Study type: Interventional

Funder types: Other

Identifiers

NCT06081738

2/2023ANSTH49

Details and patient eligibility

About

The study will assess the acute effects of sugammadex or neostigmine on renal function as determined with more specific and sensitive tests in laparoscopic cholecystectomy

Enrollment: 64 patients

Sex: All

Ages: 20 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• normal renal function (serum Cr 0.4- 1.4 g/dL)
• American Society of Anesthesiologists (ASA) Class I-II

Exclusion criteria

• Incapacity to consent.
• Pre-existing impaired kidney functions.
• Severe neuromuscular disease, as: myasthenia gravis & muscular dystrophy.
• Intra-operative bleeding
• Lengthy operations that exceed 2 hours.
• Hemodynamic changes more than 20% of the base line

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

64 participants in 2 patient groups

Neostigmine Group

Active Comparator group

Treatment:

Drug: Neostigmine

Sugammadex Group

Active Comparator group

Treatment:

Drug: Sugammadex